The RSV therapy market is characterized by a large and growing population of people at risk of infection every year. At greatest risk are infants and the elderly. No interventions are approved for…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal pharmacotherapy product approvals across different drug…
Abstract: The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12…
The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…
The tumor necrosis factor alpha (TNF-a) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. Meeting…
The U.S. asthma therapy market has long been dominated by several effective and well-established treatments, including inhaled and oral therapies, but following the recent approval of two biologics…
The United States has seen a dramatic rise in the prevalence of chronic kidney disease (CKD) and its sequelae—namely, diabetes and hypertension. Patients with CKD are typically co-managed by many…
LaunchTrends: Zarxio (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s…
The prevalence of spondyloarthritis is increasing in China, where the estimated number of total prevalent cases of ankylosing spondylitis (AS) exceeds 1.6 million. Although the total prevalence of…
Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and…
The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years,…
The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several…
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able to…
Renal Anemia | Access & Reimbursement | US examines the market access factors that influence the success of therapies for the treatment of renal anemia. The series is based on primary research data…
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including…